95 completed, 13 active not recruiting, 9 recruiting, 8 terminated. 141 Phase 3, 14 Phase 2.
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks Remibrutinib, Omalizumab - Chronic Spontaneous Urticaria | Phase 3 | Recruiting | Novartis Pharmaceuticals | 382 | 2026-09-21 | 2026-10-13 |
| Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. Autologous whole blood therapy, Desloratadine - Chronic Idiopathic Urticaria | Phase 3 | Not yet recruiting | Cairo University | 40 | 2026-04-30 | 2026-03-20 |
| Donidalorsen Treatment in Children With Hereditary Angioedema Donidalorsen - Hereditary Angioedema (HAE) | Phase 3 | Recruiting | Ionis Pharmaceuticals, Inc. | 20 | 2026-04-21 | 2026-09-02 |
| A Study of MG-K10 in Chronic Spontaneous Urticaria MG-K10 Humanized Monoclonal Antibody Injection, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 3 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 226 | 2026-04-14 | 2026-04-22 |
| Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) ADX-324 Dose Level 1, ADX-324 Dose Level 2 - Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1 | Phase 3 | Recruiting | ADARx Pharmaceuticals, Inc. | 90 | 2026-04-02 | 2026-09-04 |
| Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. JYB1904, Placebo+JYB1904 - Chronic Spontaneous Urticaria | Phase 3 | Recruiting | Jemincare | 240 | 2026-03-09 | 2026-08-03 |
| Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria ICP-332 Tablets, ICP-332 placebo Tablets - Chronic Spontaneous Urticaria (CSU) | Phase 2 / Phase 3 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 344 | 2026-02-13 | 2026-04-21 |
| A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) Barzolvolimab, Matching Placebo - Chronic Inducible Urticaria, Cold Urticaria | Phase 3 | Recruiting | Celldex Therapeutics | 240 | 2026-01-15 | 2026-10-07 |
| Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria barzolvolimab, Standard of Care - Chronic Spontaneous Urticaria | Phase 3 | Enrolling by invitation | Celldex Therapeutics | 1370 | 2025-11-25 | 2026-10-07 |
| Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency Deucrictibant, Placebo - Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | Phase 3 | Recruiting | Pharvaris Netherlands B.V. | 48 | 2025-10-16 | 2026-09-21 |
| A Long-Term Study of Navenibart in Participants With Hereditary Angioedema navenibart - Hereditary Angioedema (HAE) | Phase 3 | Enrolling by invitation | Astria Therapeutics, Inc. | 145 | 2025-10-01 | 2026-07-30 |
| STOP-HAE: A Phase 3 Study of ADX-324 in HAE ADX-324, Placebo - Hereditary Angioedema, HAE | Phase 3 | Recruiting | ADARx Pharmaceuticals, Inc. | 90 | 2025-08-28 | 2026-09-10 |
| A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines Remibrutinib, Remibrutinib matching placebo, Dupilumab - Chronic Spontaneous Urticaria (CSU) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 409 | 2025-07-11 | 2026-10-13 |
| A Study of Navenibart in Participants With Hereditary Angioedema navenibart, Placebo - Hereditary Angioedema (HAE) | Phase 3 | Active not recruiting | Astria Therapeutics, Inc. | 157 | 2025-03-20 | 2026-06-30 |
| Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Deucrictibant - Hereditary Angioedema (HAE) | Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 170 | 2025-02-01 | 2026-09-22 |
| HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) NTLA-2002, Normal Saline IV Administration - Hereditary Angioedema | Phase 3 | Active not recruiting | Intellia Therapeutics | 80 | 2025-01-15 | 2026-10-08 |
| Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema Conestat Alfa - ACE Inhibitor-Induced Angioedema | Phase 3 | Unknown | University of Cincinnati | 24 | 2024-12-01 | 2024-11-07 |
| Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Deucrictibant, Placebo - Hereditary Angioedema (HAE) | Phase 3 | Active not recruiting | Pharvaris Netherlands B.V. | 81 | 2024-12-01 | 2026-02-13 |
| Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II KVD900 150 mg, KVD900 300 mg, KVD900 600 mg - Hereditary Angioedema | Phase 3 | Completed | KalVista Pharmaceuticals, Ltd. | 36 | 2024-08-01 | 2026-08-05 |
| A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) barzolvolimab, Matching placebo - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | Celldex Therapeutics | 976 | 2024-07-19 | 2026-03-25 |
Showing 20 of 141. Sign in to see all of them.
Angioedemas, Hereditary (60) · Chronic Urticaria (47) · Angioedema (16) · Cryopyrin-Associated Periodic Syndromes (9) · Hereditary Angioedema Types I and II (6) · Hypersensitivity (6) · Cold Urticaria (5) · Multiple Pterygium Syndrome, Autosomal Dominant (5) · Acquired angioedema (3) · Chronic Inducible Urticaria (3) · Genetic Diseases, Inborn (3) · Immune System Diseases (3) · Pruritus (3) · Rhinitis, Allergic (3)
Skin and Connective Tissue Diseases (141) · Skin Diseases (140) · Hypersensitivity, Immediate (139) · Skin Diseases, Vascular (139) · Immune System Diseases (138) · Hypersensitivity (135) · Cardiovascular Diseases (69) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (69) · Vascular Diseases (69) · Genetic Diseases, Inborn (66) · Pathological Conditions, Signs and Symptoms (64) · Pathologic Processes (61) · Disease Attributes (60) · Hereditary Complement Deficiency Diseases (60)
Omalizumab (18) · Complement C1 Inhibitor Protein (13) · remibrutinib (10) · canakinumab (8) · lanadelumab (8) · Sodium Chloride (7) · icatibant (7) · levocetirizine (6) · berotralstat (5) · desloratadine (5) · ligelizumab (5) · dupilumab (4) · ecallantide (4) · sebetralstat (4) · Diphenhydramine (3)
Novartis Pharmaceuticals (24) · Shire (22) · BioCryst Pharmaceuticals (7) · CSL Behring (7) · Pharvaris Netherlands B.V. (5) · Celldex Therapeutics (4) · Charite University, Berlin, Germany (4) · KalVista Pharmaceuticals, Ltd. (4) · Takeda (4) · Genentech, Inc. (3) · Ionis Pharmaceuticals, Inc. (3) · Organon and Co (3) · Pharming Technologies B.V. (3) · Sanofi (3) · UCB Pharma (3)
United States (80) · Germany (64) · Canada (57) · Spain (52) · France (47) · United Kingdom (42) · Italy (41) · Poland (38) · Hungary (35) · Japan (34) · Australia (30) · Israel (30) · Netherlands (27) · Bulgaria (26) · Argentina (24)
Lauge Farnaes, MD (2) · M. M. Levi, Prof. Dr. (2) · Marcus Maurer, MD (2) · Anurag Relan, MD (1) · Baek-Hwan Cho, MD., PhD (1) · Bruce Zuraw, MD (1) · Cheng Zhou (1)
PMID 36326435, PMID 20818886, PMID 23312695, PMID 23548529, PMID 23878046, PMID 24712435, PMID 26054553, PMID 27424128, PMID 27540466, PMID 27939380, PMID 28390587, PMID 29655772, PMID 36408587, PMID 42159953, PMID 20818888, PMID 20819318, PMID 20920772, PMID 21130380, PMID 22765833, PMID 22856635, PMID 23484892, PMID 23548526, PMID 23987198, PMID 28284978, PMID 31161734, PMID 36153561, PMID 37028510, PMID 38008109, PMID 39193419, PMID 40043237, PMID 40380356, PMID 40469312, PMID 40886933, PMID 42268494, PMID 42297099, PMID 17073887, PMID 18668535, PMID 19494217, PMID 19767078, PMID 19860762, PMID 20674826, PMID 20818887, PMID 21195947, PMID 21859692, PMID 21884533, PMID 21988742, PMID 22123383, PMID 22136279, PMID 22152723, PMID 22192966
2019 (4), 2015 (3), 2018 (3), 2023 (3), 2004 (2), 2009 (2), 2014 (2), 2008 (1), 2025 (1)